05:05 PM EDT, 07/15/2025 (MT Newswires) -- Kezar Life Sciences ( KZR ) said Tuesday that the US Food and Drug Administration's Division of Hepatology and Nutrition has lifted the partial clinical hold on the completed phase 2a trial assessing zetomipzomib in people with autoimmune hepatitis (AIH).

Kezar said it also plans to respond to the FDA's Division of Rheumatology and Transplant Medicine with a request to lift a clinical hold on zetomipzomib in lupus nephritis based on feedback from the Independent Data Monitoring Committee and an internal analysis of safety results in all trials involving zetomipzomib.

The company's shares were rising 2.4% in recent after-hours activity.